Revvity, Inc. (RVTY) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Revvity, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Laboratory Analytical Instruments
High 146.50 at 6:30 am ET, low 141.30 at 7:00 pm ET.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
the bull case· 2
7
funds on file reporting a position in the company
n-portas of Jun 30 '260.22%
share of a sector ETF's assets as the largest fund weight on file
n-portJun 30 '26the bear case· 4
5 of 7
recent reports where moves landed below the options implied range
earnings historyimplied vs realized8 of 22
largest reporting managers cutting their stake in the latest quarter
13fJun 30 '26−10.24%
change in shares held by the largest reporting managers over the latest quarter
13fJun 30 '2620
managers whose positions together make up most of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Revvity, Inc. moves with most closely, 3 also share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 3826, Laboratory Analytical Instruments, from each company's own filings. Largest first.
A rule beside a ticker marks a company that appears in both readings.
Which of these the filings never mention ›541 managers report a position worth $12.7B between them, and 20 of them hold 80% of it.
tall tick = annual report · 1 on record
RVTY (Revvity, Inc.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.